# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Canaccord Genuity analyst Edward Nash maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and lowers the price target from...
HC Wainwright & Co. analyst Ed Arce reiterates Akero Therapeutics (NASDAQ:AKRO) with a Buy and maintains $50 price target.
Akero Therapeutics (NASDAQ:AKRO) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(...
B of A Securities analyst Alexandria Hammond reinstates Akero Therapeutics (NASDAQ:AKRO) with a Neutral and announces $30 pr...
As reported previously, the addition of EFX to GLP-1 receptor agonist therapy had a safety and tolerability profile comparable ...
The comnay announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offeri...
UBS analyst Eliana Merle maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target from $39 to $42.
HC Wainwright & Co. analyst Ed Arce maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target fr...